|
[1]
|
Paget, S. (1889) The Distribution of Secondary Growths in Cancer of the Breast. The Lancet, 133, 571-573.
https://doi.org/10.1016/S0140-6736(00)49915-0
|
|
[2]
|
Racacho, K.J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., et al. (2025) The Tumor Immune Microenvironment: Implications for Cancer Immunotherapy, Treatment Strategies, and Monitoring Approaches. Frontiers in Immunology, 16, Article 1621812.
https://doi.org/10.3389/fimmu.2025.1621812
|
|
[3]
|
Alsaafeen, B.H., Ali, B.R. and Elkord, E. (2025) Resistance Mechanisms to Immune Checkpoint Inhibitors: Updated Insights. Molecular Cancer, 24, Article No. 20.
https://doi.org/10.1186/s12943-024-02212-7
|
|
[4]
|
Pu, Y. and Ji, Q. (2022) Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. Frontiers in Immunology, 13, Article 874589.
https://doi.org/10.3389/fimmu.2022.874589
|
|
[5]
|
Lasser, S.A., Ozbay Kurt, F.G., Arkhypov, I., Utikal, J. and Umansky, V. (2024) Myeloid-Derived Suppressor Cells in Cancer and Cancer Therapy. Nature Reviews Clinical Oncology, 21, 147-164.
https://doi.org/10.1038/s41571-023-00846-y
|
|
[6]
|
Imianowski, C.J., Chen, Q., Workman, C.J. and Vignali, D.A.A. (2025) Regulatory T Cells in the Tumour Microenvironment. Nature Reviews Cancer, 25, 703-722.
https://doi.org/10.1038/s41568-025-00832-9
|
|
[7]
|
Garate-Soraluze, E., Martinez-Zubiaurre, I. and Rodriguez-Ruiz, M.E. (2026) Cancer-Associated Fibroblast Targeting Therapies as a Tool to Enhance Responses to Radiotherapy and Immunotherapy. Journal for ImmunoTherapy of Cancer, 14, e009702.
https://doi.org/10.1136/jitc-2024-009702
|
|
[8]
|
Mai, Z., Lin, Y., Lin, P., Zhao, X. and Cui, L. (2024) Modulating Extracellular Matrix Stiffness: A Strategic Approach to Boost Cancer Immunotherapy. Cell Death & Disease, 15, Article No. 307.
https://doi.org/10.1038/s41419-024-06697-4
|
|
[9]
|
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., et al. (2023) Extracellular Matrix Remodeling in Tumor Progression and Immune Escape: From Mechanisms to Treatments. Molecular Cancer, 22, Article No. 48.
https://doi.org/10.1186/s12943-023-01744-8
|
|
[10]
|
Ortmann, B.M. (2024) Hypoxia-Inducible Factor in Cancer: From Pathway Regulation to Therapeutic Opportunity. BMJ Oncology, 3, e000154.
https://doi.org/10.1136/bmjonc-2023-000154
|
|
[11]
|
Bergers, G. and Hanahan, D. (2008) Modes of Resistance to Anti-Angiogenic Therapy. Nature Reviews Cancer, 8, 592-603.
https://doi.org/10.1038/nrc2442
|
|
[12]
|
Wang, M., Chen, Y., Tian, L., Wu, C., Chen, J., Hu, J., et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. Cancer Discovery, 15, 1883-1904.
https://doi.org/10.1158/2159-8290.cd-24-1033
|
|
[13]
|
Shi, Y. and Gilkes, D.M. (2025) HIF-1 and HIF-2 in Cancer: Structure, Regulation, and Therapeutic Prospects. Cellular and Molecular Life Sciences, 82, Article No. 44.
https://doi.org/10.1007/s00018-024-05537-0
|
|
[14]
|
Lv, H., Han, X., Yang, Y., Shen, J., Yin, Y. and Liu, Y. (2025) Glutamine: A New Strategy for Targeted Metabolic Therapy in the Tumor Microenvironment. Cell Death Discovery, 11, Article No. 459.
https://doi.org/10.1038/s41420-025-02767-4
|
|
[15]
|
Shan, L., Gong, M., Zhai, D., Meng, X., Liu, J. and Lv, X. (2025) Research Progress of CD73-Adenosine Signaling Regulating Hepatocellular Carcinoma through Tumor Microenvironment. Journal of Experimental & Clinical Cancer Research, 44, Article No. 161.
https://doi.org/10.1186/s13046-025-03416-5
|
|
[16]
|
Schaub, J. and Tang, S. (2025) Beyond Checkpoint Inhibitors: The Three Generations of Immunotherapy. Clinical and Experimental Medicine, 25, Article No. 43.
https://doi.org/10.1007/s10238-024-01546-2
|
|
[17]
|
Ding, L., Guo, H., Zhang, J., Zheng, M., Zhang, W., Wang, L., et al. (2024) Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐l1. Advanced Science, 11, e2400340.
https://doi.org/10.1002/advs.202400340
|
|
[18]
|
Wang, Q., Wang, J., Yu, D., Zhang, Q., Hu, H., Xu, M., et al. (2024) Benzosceptrin C Induces Lysosomal Degradation of PD-L1 and Promotes Antitumor Immunity by Targeting DHHC3. Cell Reports Medicine, 5, Article ID: 101357.
https://doi.org/10.1016/j.xcrm.2023.101357
|
|
[19]
|
Fong, L., Hotson, A., Powderly, J.D., Sznol, M., Heist, R.S., Choueiri, T.K., et al. (2020) Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discovery, 10, 40-53.
https://doi.org/10.1158/2159-8290.cd-19-0980
|
|
[20]
|
Schiemann, K., Belousova, N., Matevossian, A., Nallaparaju, K.C., Kradjian, G., Pandya, M., et al. (2024) Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth in Vivo. Molecular Cancer Therapeutics, 23, 1517-1529.
https://doi.org/10.1158/1535-7163.mct-23-0843
|
|
[21]
|
Bendell, J., LoRusso, P., Overman, M., Noonan, A.M., Kim, D., Strickler, J.H., et al. (2023) First-in-Human Study of Oleclumab, a Potent, Selective Anti-Cd73 Monoclonal Antibody, Alone or in Combination with Durvalumab in Patients with Advanced Solid Tumors. Cancer Immunology, Immunotherapy, 72, 2443-2458.
https://doi.org/10.1007/s00262-023-03430-6
|
|
[22]
|
Xu, J., Yao, H., Wang, J., Jin, Y., Chang, W., Li, L., et al. (2025) Perineural Invasion and the “Cold” Tumor Microenvironment in Pancreatic Cancer: Mechanisms of Crosstalk and Therapeutic Opportunities. Frontiers in Immunology, 16, Article 1650117.
https://doi.org/10.3389/fimmu.2025.1650117
|
|
[23]
|
Bever, K.M., Shin, S.M., Durham, J.N., Qi, H., Hernandez, A., Coyne, E.M., et al. (2025) A Phase 2 Trial of CXCR4 Antagonism and PD1 Inhibition in Metastatic Pancreatic Adenocarcinoma Reveals Recruitment of T Cells but Also Immunosuppressive Macrophages. OncoImmunology, 14, Article ID: 2543614.
https://doi.org/10.1080/2162402x.2025.2543614
|
|
[24]
|
Wang, J., Tannous, B.A., Poznansky, M.C. and Chen, H. (2020) CXCR4 Antagonist AMD3100 (Plerixafor): From an Impurity to a Therapeutic Agent. Pharmacological Research, 159, Article ID: 105010.
https://doi.org/10.1016/j.phrs.2020.105010
|
|
[25]
|
Guo, C., Sharp, A., Gurel, B., Crespo, M., Figueiredo, I., Jain, S., et al. (2023) Targeting Myeloid Chemotaxis to Reverse Prostate Cancer Therapy Resistance. Nature, 623, 1053-1061.
https://doi.org/10.1038/s41586-023-06696-z
|
|
[26]
|
Sherry, C., Dadgar, N., Liu, Z., Fan, Y., Xiao, K., Zaidi, A.H., et al. (2025) The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis. Current Oncology, 32, Article 496.
https://doi.org/10.3390/curroncol32090496
|
|
[27]
|
Chen, K., Li, X., Dong, S., Guo, Y., Luo, Z., Zhuang, S., et al. (2025) Modulating Tumor-Associated Macrophages through CSF1R Inhibition: A Potential Therapeutic Strategy for HNSCC. Journal of Translational Medicine, 23, Article No. 27.
https://doi.org/10.1186/s12967-024-06036-3
|
|
[28]
|
Quail, D.F., Bowman, R.L., Akkari, L., Quick, M.L., Schuhmacher, A.J., Huse, J.T., et al. (2016) The Tumor Microenvironment Underlies Acquired Resistance to CSF-1R Inhibition in Gliomas. Science, 352, aad3018.
https://doi.org/10.1126/science.aad3018
|
|
[29]
|
Steeghs, N., Gomez-Roca, C., Korakis, I., Gort, E., De Winter, H., Stojcheva, N., et al. (2026) Tumor-Localized CD40 Agonism with MP0317, a FAP X CD40 Darpin, Reprograms the Tumor Microenvironment in Patients with Advanced Solid Tumors: An Open-Label, Nonrandomized, Dose-Escalation Phase 1 Study. Nature Cancer, 7, 810-822.
https://doi.org/10.1038/s43018-026-01150-1
|
|
[30]
|
Meric-Bernstam, F., Sweis, R.F., Hodi, F.S., Messersmith, W.A., Andtbacka, R.H.I., Ingham, M., et al. (2021) Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research, 28, 677-688.
https://doi.org/10.1158/1078-0432.ccr-21-1963
|
|
[31]
|
Bukhalid, R.A., Duvall, J.R., Lancaster, K., Catcott, K.C., Malli Cetinbas, N., Monnell, T., et al. (2025) XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells. Clinical Cancer Research, 31, 1766-1782.
https://doi.org/10.1158/1078-0432.ccr-24-2449
|
|
[32]
|
Fabre, M., Ferrer, C., Domínguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., et al. (2020) OMTX705, a Novel Fap-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clinical Cancer Research, 26, 3420-3430.
https://doi.org/10.1158/1078-0432.ccr-19-2238
|
|
[33]
|
Melero, I., Tanos, T., Bustamante, M., Sanmamed, M.F., Calvo, E., Moreno, I., et al. (2023) A First-in-Human Study of the Fibroblast Activation Protein-Targeted, 4-1BB Agonist RO7122290 in Patients with Advanced Solid Tumors. Science Translational Medicine, 15, eabp9229.
https://doi.org/10.1126/scitranslmed.abp9229
|
|
[34]
|
Perez-Gracia, J.L., Mellado, B., Hansen, A.R., Alonso-Gordoa, T., Gomez-Roca, C., Løvendahl Eefsen, R., et al. (2026) Simlukafusp Alfa (FAP-IL2v) Plus Atezolizumab with or without Bevacizumab in Unresectable, Metastatic Renal Cell Carcinoma: A Randomized, Open-Label Phase Ib Study. Journal for ImmunoTherapy of Cancer, 14, e012466.
https://doi.org/10.1136/jitc-2025-012466
|
|
[35]
|
Tobin, R.P., Cogswell, D.T., Cates, V.M., Davis, D.M., Borgers, J.S.W., Van Gulick, R.J., et al. (2022) Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clinical Cancer Research, 29, 1209-1219.
https://doi.org/10.1158/1078-0432.ccr-22-2495
|
|
[36]
|
Perez, K.J., Dias Costa, A., Jordan, A., Karasic, T.B., Elganainy, D., Kim, S., et al. (2026) Gemcitabine and Nab-Paclitaxel with or without the VDR Agonist Paricalcitol for Metastatic Pancreatic Cancer: A Randomized, Multiarm, Run-In Phase Trial. Nature Cancer, 7, 928-943.
https://doi.org/10.1038/s43018-026-01165-8
|
|
[37]
|
Ferreira, S., Saraiva, N., Rijo, P. and Fernandes, A.S. (2021) LOXL2 Inhibitors and Breast Cancer Progression. Antioxidants, 10, Article 312.
https://doi.org/10.3390/antiox10020312
|
|
[38]
|
Zaffryar-Eilot, S., Marshall, D., Voloshin, T., Bar-Zion, A., Spangler, R., Kessler, O., et al. (2013) Lysyl Oxidase-Like-2 Promotes Tumour Angiogenesis and Is a Potential Therapeutic Target in Angiogenic Tumours. Carcinogenesis, 34, 2370-2379.
https://doi.org/10.1093/carcin/bgt241
|
|
[39]
|
Vachhani, P., Tan, P., Watson, A., Wu, S., Baker, R., Cheung, S., et al. (2025) A Phase I/IIA Trial of PXS-5505, a Novel Pan-Lysyl Oxidase Inhibitor, in Advanced Myelofibrosis. Haematologica, 110, 2376-2387.
https://doi.org/10.3324/haematol.2024.287231
|
|
[40]
|
Ai, J., Li, H., Zhang, M., Liu, J., Liu, L. and Sun, C. (2026) Mechanical Microenvironment in Tumor Immune Evasion: Bidirectional Regulation between Matrix Stiffness and Immune Cells and Its Therapeutic Implications. International Journal of Biological Sciences, 22, 280-307.
https://doi.org/10.7150/ijbs.121356
|
|
[41]
|
Cheng, A., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T., et al. (2022) Updated Efficacy and Safety Data from Imbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma. Journal of Hepatology, 76, 862-873.
https://doi.org/10.1016/j.jhep.2021.11.030
|
|
[42]
|
Ebrahimi, N., Fardi, E., Ghaderi, H., Palizdar, S., Khorram, R., Vafadar, R., et al. (2023) Receptor Tyrosine Kinase Inhibitors in Cancer. Cellular and Molecular Life Sciences, 80, Article No. 104.
https://doi.org/10.1007/s00018-023-04729-4
|
|
[43]
|
Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., et al. (2024) Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant. JAMA, 332, 561-570.
https://doi.org/10.1001/jama.2024.10613
|
|
[44]
|
Oura, K., Morishita, A., Tadokoro, T., Fujita, K., Tani, J. and Kobara, H. (2024) Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 25, Article 13590.
https://doi.org/10.3390/ijms252413590
|
|
[45]
|
Socinski, M.A., Nishio, M., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., et al. (2021) IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology, 16, 1909-1924.
https://doi.org/10.1016/j.jtho.2021.07.009
|
|
[46]
|
Cousin, S., Guégan, J., Palmieri, L.J., Metges, J.P., Pernot, S., Bellera, C.A., et al. (2025) Regorafenib Plus Avelumab in Advanced Gastroenteropancreatic Neuroendocrine Neoplasms: A Phase 2 Trial and Correlative Analysis. Nature Cancer, 6, 584-594.
https://doi.org/10.1038/s43018-025-00916-3
|
|
[47]
|
Choueiri, T.K., Motzer, R.J., Karam, J.A., Yip, W., Suárez, C., Ye, D., et al. (2026) Adjuvant Pembrolizumab Plus Belzutifan for Renal-Cell Carcinoma. New England Journal of Medicine, 395, 32-43.
https://doi.org/10.1056/nejmoa2518245
|
|
[48]
|
Logsdon, D.P., Shah, F., Carta, F., Supuran, C.T., Kamocka, M., Jacobsen, M.H., et al. (2018) Blocking HIF Signaling via Novel Inhibitors of CA9 and APE1/Ref-1 Dramatically Affects Pancreatic Cancer Cell Survival. Scientific Reports, 8, Article No. 13759.
https://doi.org/10.1038/s41598-018-32034-9
|
|
[49]
|
Mboge, M.Y., Mahon, B.P., Lamas, N., Socorro, L., Carta, F., Supuran, C.T., et al. (2017) Structure Activity Study of Carbonic Anhydrase IX: Selective Inhibition with Ureido-Substituted Benzenesulfonamides. European Journal of Medicinal Chemistry, 132, 184-191.
https://doi.org/10.1016/j.ejmech.2017.03.026
|
|
[50]
|
Long, G.V., Dummer, R., Hamid, O., Gajewski, T.F., Caglevic, C., Dalle, S., et al. (2019) Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma (ECHO-301/KEYNOTE-252): A Phase 3, Randomised, Double-Blind Study. The Lancet Oncology, 20, 1083-1097.
https://doi.org/10.1016/s1470-2045(19)30274-8
|
|
[51]
|
Vagaggini, C., D’Ursi, P., Poggialini, F., Fossa, P., Francesconi, V., Trombetti, G., et al. (2025) Deciphering the Landscape of Allosteric Glutaminase 1 Inhibitors as Anticancer Agents. Bioorganic Chemistry, 161, Article ID: 108523.
https://doi.org/10.1016/j.bioorg.2025.108523
|
|
[52]
|
Szemerédi, N., Schelz, Z., Horvath, D.A., Rácz, B., Szatmári, A.G., Muddather, H.F., et al. (2024) Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines. Pharmaceutics, 16, Article 877.
https://doi.org/10.3390/pharmaceutics16070877
|
|
[53]
|
Huang, R., Wang, H., Hong, J., Wu, J., Huang, O., He, J., et al. (2023) Targeting Glutamine Metabolic Reprogramming of SLC7A5 Enhances the Efficacy of Anti-PD-1 in Triple-Negative Breast Cancer. Frontiers in Immunology, 14, Article 1251643.
https://doi.org/10.3389/fimmu.2023.1251643
|
|
[54]
|
Wang, M., Zhou, Q., Cao, T., Li, F., Li, X., Zhang, M., et al. (2025) Lactate Dehydrogenase A: A Potential New Target for Tumor Drug Resistance Intervention. Journal of Translational Medicine, 23, Article No. 713.
https://doi.org/10.1186/s12967-025-06773-z
|
|
[55]
|
Halford, S., Veal, G.J., Wedge, S.R., Payne, G.S., Bacon, C.M., Sloan, P., et al. (2023) A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research, 29, 1429-1439.
https://doi.org/10.1158/1078-0432.ccr-22-2263
|
|
[56]
|
Naing, A., Papadopoulos, K.P., Pishvaian, M.J., Rahma, O., Hanna, G.J., Garralda, E., et al. (2024) First-in-Human Phase 1 Study of the Arginase Inhibitor INCB001158 Alone or Combined with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumours. BMJ Oncology, 3, e000249.
https://doi.org/10.1136/bmjonc-2023-000249
|
|
[57]
|
Kakarla, S., Chow, K.K., Mata, M., Shaffer, D.R., Song, X., Wu, M., et al. (2013) Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma. Molecular Therapy, 21, 1611-1620.
https://doi.org/10.1038/mt.2013.110
|
|
[58]
|
Wang, L.S., Lo, A., Scholler, J., Sun, J., Majumdar, R.S., Kapoor, V., et al. (2014) Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity. Cancer Immunology Research, 2, 154-166.
https://doi.org/10.1158/2326-6066.cir-13-0027
|
|
[59]
|
Petrausch, U., Schuberth, P.C., Hagedorn, C., Soltermann, A., Tomaszek, S., Stahel, R., et al. (2012) Re-Directed T Cells for the Treatment of Fibroblast Activation Protein (FAP)-Positive Malignant Pleural Mesothelioma (FAPME-1). BMC Cancer, 12, Article No. 615.
https://doi.org/10.1186/1471-2407-12-615
|
|
[60]
|
Li, T., Niu, M., Zhang, W., Qin, S., Zhou, J. and Yi, M. (2024) CAR-NK Cells for Cancer Immunotherapy: Recent Advances and Future Directions. Frontiers in Immunology, 15, Article 1361194.
https://doi.org/10.3389/fimmu.2024.1361194
|
|
[61]
|
Li, N., Geng, S., Dong, Z., Jin, Y., Ying, H., Li, H., et al. (2024) A New Era of Cancer Immunotherapy: Combining Revolutionary Technologies for Enhanced CAR-M Therapy. Molecular Cancer, 23, Article No. 117.
https://doi.org/10.1186/s12943-024-02032-9
|
|
[62]
|
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L.T., et al. (2020) The Human Tumor Microbiome Is Composed of Tumor Type-Specific Intracellular Bacteria. Science, 368, 973-980.
https://doi.org/10.1126/science.aay9189
|
|
[63]
|
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., et al. (2019) Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 178, 795-806.e12.
https://doi.org/10.1016/j.cell.2019.07.008
|
|
[64]
|
Fu, A., Yao, B., Dong, T., Chen, Y., Yao, J., Liu, Y., et al. (2022) Tumor-Resident Intracellular Microbiota Promotes Metastatic Colonization in Breast Cancer. Cell, 185, 1356-1372.e26.
https://doi.org/10.1016/j.cell.2022.02.027
|
|
[65]
|
Galeano Niño, J.L., Wu, H., LaCourse, K.D., Kempchinsky, A.G., Baryiames, A., Barber, B., et al. (2022) Effect of the Intratumoral Microbiota on Spatial and Cellular Heterogeneity in Cancer. Nature, 611, 810-817.
https://doi.org/10.1038/s41586-022-05435-0
|
|
[66]
|
Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillère, R., et al. (2018) Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. Science, 359, 91-97.
https://doi.org/10.1126/science.aan3706
|
|
[67]
|
Davar, D., Dzutsev, A.K., McCulloch, J.A., Rodrigues, R.R., Chauvin, J., Morrison, R.M., et al. (2021) Fecal Microbiota Transplant Overcomes Resistance to Anti-PD-1 Therapy in Melanoma Patients. Science, 371, 595-602.
https://doi.org/10.1126/science.abf3363
|
|
[68]
|
Luke, J.J., Piha-Paul, S.A., Medina, T., Verschraegen, C.F., Varterasian, M., Brennan, A.M., et al. (2023) Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical Cancer Research, 29, 2435-2444.
https://doi.org/10.1158/1078-0432.ccr-23-0118
|
|
[69]
|
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., et al. (2016) Clinical Trial of Blood-Brain Barrier Disruption by Pulsed Ultrasound. Science Translational Medicine, 8, 343re2.
https://doi.org/10.1126/scitranslmed.aaf6086
|
|
[70]
|
Gomerdinger, V.F., Nabar, N. and Hammond, P.T. (2025) Advancing Engineering Design Strategies for Targeted Cancer Nanomedicine. Nature Reviews Cancer, 25, 657-683.
https://doi.org/10.1038/s41568-025-00847-2
|